 |
|
|
| |
HIV-1 RNA BLIPS AND LOW-LEVEL REPLICATION DURING PHASE III/IIIB CABOTEGRAVIR + RILPIVIRINE LONG-ACTING STUDIES ARE SIMILAR TO ORAL
3-DRUG THERAPY AND NOT ASSOCIATED WITH WEEK 48 VIROLOGIC OUTCOME
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Christine Talarico,1 Sterling Wu,2 Ojesh Upadhyay,2 Marty St. Clair,1 Veerle Van Eygen,3 Krischan Hudson,1 Sandy Griffith,1 Conn Harrington,1 Jan van Lunzen,4 David Margolis,1 William Spreen1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Upper Providence, PA, USA; 3Janssen Research and Development, Beerse, Belgium; 4ViiV Healthcare, London, UK
References: 1. Orkin et al. N Engl J Med. 2020;382:1124-1135. 2. Swindells et al. N Engl J Med. 2020;382:1112-1123. 3. Overton et al. CROI 2020; Boston, MA. Abstract 34.
4. Wang et al. HIV Glasgow 2018; Glasgow, UK. Poster P313. 5. Gunthard et al. Clin Infect Dis. 2019;68:177-187. 6. McClernon et al. AMPAM 2011; Grapevine, TX. Poster ID13.
|
| |
|
|
|
|
|
